Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • Sep 23, 2014

166_ip_2014-09-23_d499b85f-9f13-4bba-bba8-2e28ab00030b.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

A Leading Global Health Care Group

Berenberg Bank & Goldman Sachs – 3rd German Corporate Conference September 23, 2014

For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.

Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Strong and Balanced Health Care Portfolio

Dialysis products and services

Ownership: 31% Ownership: 100% Ownership: 100% Ownership: 77%

Hospital supplies Hospital operations Hospital projects and services

i
b
i
2
0
1
3
G
N
I
C
t
t
t
o
p
e
n
c
o
m
e
o
n
o
n
r
u
r
u
2
%
5		 6
%
4		 2
6
%		 3
%

Favorable Industry Dynamics

Aging population and higher incidence of chronic diseases World population age 60+ will more than double by 2050 to >2 bn (OECD)

Increasing health care spending in emerging markets

Increasing health care coverage and per capita spending (e.g. India: US\$59, China: US\$278, vs. USA: US\$8,608; WHO)

Continuing growth of generics

Approx. US\$19 bn branded IV drug sales (base: 2013) go off-patent in the U.S. by 2023

Rise of private providers in health care services

Further privatization of German hospital market Global opportunity to provide dialysis services (e.g. China, India)

Fresenius Group 2013: New Sales and Earnings Records – >€1 billion Net Income One Year Ahead of Plan

Before special items

Fresenius Group: Financial Results

l
S
a
e
s		 1
E
B
I
T		 1
i
N
t
e
n
c
o
m
e
/
H
1
1
4		 €
1
0
3
3
7
m
,		 €
1
4
0
3
m
,		 €
4
8
7
m
h
G
t
t
t
t
o
a
c
o
n
s
a
n
r
w
t
c
e
n
c
a
e
s
u
r
r
y
r		 2
%
1		 0
%		 3
%
h
l
G
t
t
t
o
a
a
c
a
r
w
u
t
c
e
n
c
a
e
s
u
r
r
y
r		 %
7		 3
%
-		 %
1

Before one-time items

Fresenius Group: Financial Results by Business Segment

/
H
1
1
4		 i
F
r
e
s
e
n
u
s
d
i
l
M
C
e
c
a
a
r
e		 i
F
r
e
s
e
n
u
s
b
i
K
a		 i
F
r
e
s
e
n
u
s
l
i
H
e
o
s		 i
F
r
e
s
e
n
u
s
d
V
a
m
e
l
S
a
e
s
h
G
t
r
o
w		 \$
S
3
9
8
U
7
m
,
5
%		 €
2
4
6
6
m
,
2
%
-		 €
2
5
2
1
m
,
4
9
%		 €
3
9
8
m
5
%
-
E
B
I
T
h
G
t
r
o
w		 \$
S
0
0
U
1
1
m
,
4
%
-		 €
4
1
1
m
1
2
%
-		 €
2
5
0
m
4
0
%		 €
1
5
m
0
%

Q2/2014 Business Update

Operations & Markets

North America

  • Propofol market share down by 3%-5% since Q1, additional 7%-8% attributable to IMS reporting change
  • Drug shortage Sodium Chloride 0.9% (500/1000 ml) Kabi supply started in Q2; sales ~€3 m

Europe / Asia-Pacific / Latin America

  • Europe: 3% organic sales growth (Q1: -2%); 5% organic sales growth excl. HES; no further impact from Russia distribution change
  • Asia-Pacific: 9% organic sales growth (Q1: 3%); 11% organic sales growth excl. HES; 2013 China price cuts no longer impacting growth
  • Q2 acquisitions in Brazil and Ecuador expanding product portfolio and market presence; FY 2013 sales ~€47 m
  • HES: €18 m sales decline yoy; Q2 sales stabilized at Q1 level

Q2/2014 Business Update

Operations & Markets

l
k
b
O
h
l
k
H
i
H
E
L
I
S,
R
ö
K
i
i
t
t
t
t
o
s
p
a
n
e
o
e
n
e
e
e
e
n
n-
n
m
w
r
v
u
r
w
u
-
,
k
l
d
Q
A
i
i
4
t
t
t
t
s
e
p
o
s
e
p
e
c
e
o
s
a
n
x
r
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Fresenius Group: 2014 Financial Outlook by Business Segment / New: HELIOS incl. Acquired Rhön Hospitals

O
l
d		 N
e
w
i
F
r
e
s
e
n
u
s
b
i
K
a		 S
l
h
t
i
a
e
s
g
r
o
w
o
r
g
a
n
c
E
B
I
T
i
m
a
g
n
r		 %
6
%
4
–
1
6
5
%
1
8
%
–
i
F
r
e
s
e
n
u
s
1
l
i
H
e
o
s		 S
l
h
t
i
a
e
s
g
r
o
w
o
r
g
a
n
c
l
b
d
S
i
i
i
t
t
a
e
s
c
o
n
o
n
a
c
q
e
r
u
u
r
h
l
i
t
o
s
p
a
s
l
h
d
S
i
t
a
e
s
g
o
a
c
q
e
r
w
u
r
h
l
i
t
i
o
s
p
a
s
o
g
a
n
c
r
l
h
h
l
E
B
I
T
H
i
R
ö
i
t
+
e
o
s
n
o
s
p
a
s		 3
%
%
5
–		 b
€
1
8
n
~
3
%
5
%
–
€
5
4
0
5
6
0
m
–
i
F
r
e
s
e
n
u
s
d
V
a
m
e		 l
h
S
t
i
a
e
s
g
r
o
w
o
g
a
n
c
r
h
E
B
I
T
t
g
o
r
w		 5
%
1
0
%
–
5
%
1
0
%
–

1 Before integration costs for acquired hospitals and disposal gains (two HELIOS hospitals; Rhön stake )

Fresenius Group: 2014 Financial Outlook

O
l
d		 1
N
e
w
h
R
t
e
v
e
n
u
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 1
2
%
1
5
%
-		 1
4
%
1
6
%
‒
2
h
i
N
t
t
e
n
c
o
m
e
g
o
r
w
t
t
t
a
c
o
n
s
a
n
c
e
n
c
u
r
r
y		 2
%
%
5
‒

1 Following acquisitions at Fresenius Medical Care

2 Net income attributable to shareholders of Fresenius SE& Co.KGaA before integration costs (Fenwal; acquired Rhön hospitals) and disposal gains (two HELIOS hospitals; Rhön stake) Guidance includes acquired Rhön hospitals

Fresenius Group: Attractive Mid-Term Growth Prospects

Strong and Balanced Health Care Portfolio

Attachments

Fresenius Group: Profit and Loss Statement

€
m		 /
Q
2
1
4		 /
H
1
1
4		 h
/
G
Q
2
1
4
Y
Y
t
r
o
w
o
l
t
a
c
a
u
t
a
e
s
r		 t
t
c
o
n
s
a
n
t
a
e
s
r
l
S
a
e
s		 5
5
2
1
,		 1
0
7
3
3
,		 8
%		 1
3
%
1
E
B
I
T		 7
6
0		 1
4
0
3
,		 1
%		 5
%
N
i
t
t
t
e
n
e
r
e
s		 1
4
5
-		 2
8
3
-		 3
%		 1
%
-
I
t
n
o
m
e
a
e
s
c
x		 9
9
1
-		 3
3
2
-		 8
%
1
-		 2
3
%
-
2
N
i
t
e
n
c
o
m
e		 2
5
9		 4
8
7		 0
%		 3
%

1 2014 before integration costs (Fenwal - Q2: €2 m / H1: €3 m; acquired Rhön hospitals - Q2: €8 m / H1: €8 m) and disposal gains (two HELIOS hospitals - Q2: €0 m / H1: €22 m; Rhön Stake - Q2: €35 m / H1: €35 m); 2013 before integration costs (Fenwal - Q2: €20 m; H1: €27 m) 2

Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2014 before integration costs (Fenwal - Q2: €1 m / H1: €2 m; acquired Rhön hospitals - Q2: €6 m / H1: €6 m) and disposal gains (two HELIOS hospitals - Q2: €0 m / H1: €21 m; Rhön Stake - Q2: €34 m / H1: €34 m); 2013 before integration costs (Fenwal - Q2: €15 m; H1: €20 m)

Fresenius Kabi: Organic Sales Growth Accelerating

€
m		 /
H
1
1
4		 /
3
H
1
1		 i
O
r
g
a
n
c
H
1
Y
Y
o		 h
G
t
r
o
w
Q
2
Y
Y
o
f
h
i
I
T
n
s
o
n
e
a
p
u
r
y		 6
4
7		 0
0
5		 %
1		 3
%
I.
V
D
g
r
u
s		 8
6
8		 8
9
3		 %
1		 3
%
l
l
C
i
i
i
i
N
t
t
n
c
a
o
n
u
r		 6
6
2		 6
6
3		 %
5		 8
%
d
l
/
M
i
D
i
e
c
a
e
c
e
s
v
f
i
h
l
T
T
a
n
s
s
o
n
e
c
n
o
o
g
r
u
y		 6
0
4		 6
3
4		 2
%		 2
%
l
l
T
t
o
a
s
a
e
s		 2
6
6
4
,		 2
9
5
1
,		 2
%		 %
4

Fresenius Kabi: Organic Sales Growth Accelerating

€
m		 /
H
1
1
4		 /
H
1
1
3		 O
i
r
g
a
n
c
1
H
Y
Y
o		 h
G
t
r
o
w
Q
2
Y
Y
o
E
o
p
e
u
r		 1
0
2
4
,		 1
0
3
0
,		 1
%		 3
%
h
N
A
i
t
o
m
e
c
a
r
r		 7
4
7		 7
8
4		 0
%		 1
%
f
A
i
P
i
i
s
a
a
c
c
-		 4
6
4		 4
5
6		 6
%		 9
%
/
f
L
i
A
i
A
i
t
a
n
m
e
r
c
a
r
c
a		 2
3
1		 2
9
4		 1
1
%		 1
1
%
l
l
T
t
o
a
s
a
e
s		 2
6
6
4
,		 2
9
5
1
,		 2
%		 %
4

Fresenius Kabi: EBIT Margin Fully in Line with Guidance

€
m		 /
Q
2
1
4		 /
H
1
1
4		 /
3
H
1
1		 h
G
t
o
r
w
Q
2
Y
Y
o
E
u
r
o
p
e
M
i
a
g
n
r		 8
1
1
5.
5
%		 1
5
0
1
4
6
%		 1
7
8
3
1
7.
%		 1
4
%
-
h
N
A
i
t
o
r
m
e
r
c
a
M
i
a
g
n
r		 1
3
9
3
8.
1
%		 2
8
6
3
8.
3
%		 2
9
1
3
7.
1
%		 1
%
f
/
/
f
i
i
i
i
i
i
A
P
L
t
A
A
s
a
a
c
c
a
n
m
e
c
a
c
a
r
r
-
M
i
a
r
g
n		 9
5
1
6.
2
%		 1
0
8
1
5.
5
%		 1
2
0
1
7.
0
%		 %
7
C
d
C
&
R
D
t
t
o
r
p
o
r
a
e
a
n
o
r
p
o
r
a
e		 6
9
-		 3
3
1
-		 2
0
1
-		 %
2
8
-
l
T
E
B
I
T
t
o
a
i
M
a
g
n
r		 2
1
0
1
6
8
%		 4
1
1
1
6
7
%		 4
6
9
1
8
6
%		 9
%
-
5
%
c
c
-

EBIT excluding integration costs (Fenwal - Q2: €2million / H1: €3 million)

Fresenius Helios: Sales and EBIT Growth Driven by First-Time Consolidation of Rhön Hospitals

€
m		 /
Q
2
1
4		 /
H
1
1
4		 /
H
1
1
3		 h
G
t
r
o
w
Q
2
Y
Y
o
l
l
T
t
o
a
s
a
e
s		 2
9
1
4
,		 2
2
5
1
,		 6
9
1
5
,		 2
%
5
E
B
I
T
b
l
h
d
l
f
l
E
i
i
i
i
t
t
s
a
s
e
c
n
c
p
o
r
o
o
M
i
a
g
n
r		 9
6
2
%
1
1.		 8
1
4
0.
%
1
7		 1
7
5
0.
6
%
1		 7
%
/
A
i
i
i
D
i
i
t
t
t
c
q
u
s
o
n
s
v
e
s
u
r
e
s
(
l
d
/
d
l
d
)
i
i
i
i
1
t
t
<
c
o
n
s
o
a
o
n
e
c
o
n
s
o
a
o
n
y
r		 4
0		 6
6		 4
l
T
E
B
I
T
t
o
a		 1
3
6		 2
5
0		 1
7
9		 8
4
%
i
M
a
r
g
n		 0
%
1
5		 9
9
%		 0
6
%
1

Before integration costs (acquired Rhön hospitals: €8 million) and disposal gains (two HELIOS hospitals: €22 million; Rhön stake: €35 million)

Fresenius Helios: Performance Indicators

/
H
1
1
4		 /
3
H
1
1		 C
h
e
a
n
g
1
f
h
l
N
i
t
o
o
o
s
p
a
s
l
A
t
i
i
c
u
e
c
a
r
e
c
n
c
s
-
l
P
i
i
t-
t
o
s
a
c
e
c
a
e
c
n
c
s
u
r
-		 1
1
0
8
6
2
4		 7
4
5
1
2
3		 4
9
%
6
9
%
4
%
1
f
b
d
N
o
o
e
s
l
A
t
i
i
c
u
e
c
a
r
e
c
n
c
s
-
l
P
i
i
t-
t
o
s
a
c
e
c
a
e
c
n
c
s
u
r
-		 3
4
0
4
8
,
2
8,
9
0
5
5,
1
4
3		 2
3
5
0
2
,
8,
8
8
1
5
4,
6
1
7		 4
5
%
3
%
5
1
1
%
d
A
i
i
m
s
s
o
n
s
(
)
A
t
i
t
i
t
c
e
c
a
e
n
p
a
e
n
u
r
-		 8
2
0
5
5
7,		 3
8
3,
0
0
5		 6
%
4
O
c
c
p
a
n
c
u
y
P
t-
t
o
s
a
c
u
e
c
a
r
e
-		 8
2
%		 8
2
%
l
h
f
(
d
)
A
t
t
e
a
g
e
e
n
g
o
s
a
a
s
v
r
y
y
A
t
c
u
e
c
a
r
e
-
P
t-
t
o
s
a
c
e
c
a
e
u
r
-		 6.
6
2
6.
8		 6.
6
2
7.
2

December 31, 2013

Fresenius Helios: 2013 Clinic Development Plan

i
f
l
i
Y
P
t
e
a
s
n
o
o
o
r
r
1
<		 1 2 3 4 5 6 6
>		 l
T
t
o
a
f
l
N
i
i
o.
o
c
n
c
s		 2
1		 3 1 6 4 8
4		 7
4
(
)
R
€
e
e
n
e
m
v
u		 -
-		 3
9
0		 1
5
5		 8
3		 -
-		 1
9
6		 3
1
2		 8
2,
1
9		 8
3,
2
9
T
t
a
r
g
e
(
%
)
E
B
I
T
i
m
a
r
g
n		 - 2.
0		 0
4		 6.
0		 8.
0		 0.
0
1		 2.
0
1		 2.
0-
0
1
1
5.
E
B
I
T
(
€
)
m		 - 7.
8		 6.
2		 2.
3		 - 1
9
6		 3
7.
4		 2
6
3.
8		 3
3
7.
1
d
R
t
e
p
o
e
r
(
)
E
B
I
T
i
%
m
a
r
g
n		 - 1
1.
4		 0.
5		 3.
4		 - 7.
5		 1
2.
8		 1
3.
0		 1
1.
8
(
)
E
B
I
T
€
m		 - 4
4
6		 0.
8		 1.
3		 - 1
4
7		 3
9
9		 2
8
5.
9		 3
8
7.
2
f
l
N
i
i
t
t
>
o.
o
c
n
c
s
a
g
e
r		 - 9 1 - - 2 2 1
7		 3
1
f
l
N
i
i
t
t
o.
o
n
<
g
e
c
c
s
a
r
S
IFR		 - 3 2 1 - 4 2 3
1		 4
3

Fresenius Vamed: Sales and EBIT in Line with Expectations

€
m		 /
H
1
1
4		 /
3
H
1
1		 G
h
t
r
o
w
b
P
j
i
t
o
e
c
s
n
e
s
s
r
u		 1
7
3		 2
0
8		 1
7
%
-
b
S
i
i
e
r
v
c
e
u
s
n
e
s
s		 2
2
5		 2
3
1		 6
%
l
l
T
t
o
a
s
a
e
s		 3
9
8		 4
2
1		 5
%
-
l
T
E
B
I
T
t
o
a		 1
5		 1
5		 0
%
i
M
a
r
g
n		 3
8
%		 3
6
%
1
O
d
i
k
t
e
a
e
r
r
n		 3
0
0		 3
1
1		 %
4
-
1
O
d
b
k
l
e
o
r
r
a
c
g		 2
6
2
1
,		 2
3
9
1
1
,		 %
1
1

Project business only

2December 31, 2013

Consistent Cash Generation and Proven Track Record of Deleveraging

Cash Flow Development LTM

€
m		 i
O
C
F
t
p
e
r
a
n
g		 (
)
C
t
a
p
e
x
n
e		 1
h
l
F
C
F
r
e
e
a
s
o
w
/
L
T
M
H
1
1
4		 i
L
T
M
M
a
r
g
n		 /
L
T
M
H
1
1
4		 i
L
T
M
M
a
r
g
n		 /
L
T
M
H
1
1
4		 i
L
T
M
M
a
r
g
n
6
4
5		 9
%
4		 3
3
5
-		 6
8
%
-		 3
0
1		 2
6
%
3
8
3		 9
1
%		 2
0
4
-		 4
9
%
-		 1
7
9		 3
4
2
%
3
4
-		 3
%
4
-		 0
1
-		 0
%
1
-		 4
4
-		 %
4
4
-
Co
/
te
rp
or
a
O
he
t
r		 7 /
n
a		 6
-		 /
n
a		 1 /
n
a
l.
F
M
C
ex
c		 8
2
1		 2
8
8
%		 5
5
5
-		 5
4
%
-		 2
6
6		 2
3
4
%
G
ro
up		 2
2
3
1
,		 0
%
1
1		 6
3
1
1
-
,		 %
5
5
-		 9
6
0		 6
%
4

1 Before Acquisitions and Dividends

2 Incl. FMC dividend

3 Understated: 5.3% excluding €44 million of capex commitments from acquisitions

Margin = in % of sales

Fresenius Group: Debt and Interest Ratios

Before integration costs (Fenwal: €3 million; acquired Rhön hospitals: €8 million) and disposal gains (two HELIOS hospitals: €22 million; Rhon stake: €35 million)

32013 before integration costs (Fenwal: €54 million); pro forma excluding advances made for the acquisition of hospitals from Rhön-Klinikum AG (€2.18 bn)

2Pro forma including Rhön hospitals and excluding two HELIOS hospitals

Share Information

Share key facts

Number of shares1 540,511,632 Ticker symbol FRE Bloomberg symbol FRE GR Reuters symbol FREG.de

WKN / ISIN 578560 / DE0005785604

ADR key facts

Ticker symbol FSNUY Depositary bank Deutsche Bank

Ratio 4 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053 Exchange OTCQX International Premier Structure Sponsored Level I ADR

As of August 1, 2014

Financial Calendar 2014

04.11.2014 Report on 1st – 3rd quarter 2014

Please note that these dates could be subject to modifications.

Contact

Birgit Grund SVP Investor Relations Fresenius SE & Co. KGaA

Telephone: +49 6172 608-2485 e-mail: [email protected]

For further information and current news: http://www.fresenius.com

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.